Global DPP IV Inhibitors Industry

NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global DPP IV Inhibitors Industry

http://www.reportlinker.com/p0681891/Global-DPP-IV-Inhibitors-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharma

This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs – Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and Alogliptin among others). The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 31 companies including many key and niche players such as Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly And Company, Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 4

Market Outlook 4

Major Events in the DPP-IV Inhibitor Space 5

Current and Future Analysis 5

The Diabetic Epidemic 6

Type-2 Diabetes Treatment - A Brief Overview 6

Overview of Drug Classes in Anti-Diabetic Drugs Category 7

Rationale for Use of DPP-4 Inhibitors 7

Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction 8

DPP-4 Inhibitors - Complementing Existing Approaches 8

Outlook for DPP-IV Therapies Remains Robust 8

DPP-4 Inhibitors versus GLP-1 Receptor Agonists 9

Distinction Between GLP-1 Receptor Agonists and DPP-4 Inhibitors 9

Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market 9

Limited Efficacy Drives Use of Combination Products 10

3. DPP-IV INHIBITORS - MARKET DYNAMICS 11

The DPP-4 Inhibitor Domain 11

Select Approved DPP-4 Inhibitors in Developed Markets 11

Januvia - The Leading DPP-IV Inhibitor Drug Worldwide 12

Huge Potential Exists for Januvia and Other DPP-4 Inhibitors 12

Januvia to Concede Market Share; Yet Remain the Market Leader 12

"Me-Too" Competition Fails to Halt Januvia's Success 13

Galvus Sales Garner Significant Growth 13

A Comparison of Januvia and Galvus 13

Pharmacological Comparison of Sitagliptin and Vildagliptin 14

Anti-Diabetics Arena in a Quandary as Late Stage Development

Drug Faces Trouble 14

Increasing Competition to Taper Opportunities for Pipeline Drugs 15

4. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS 16

Januvia® Franchise (Merck & Co.) 16

Table 1: Global Sales of Januvia (Sitagliptin) Franchise by

Drug (2007-2010): Value Sales in US$ Million for Januvia and

Janumet (includes corresponding Graph/Chart) 17

Table 2: Global Sales of Januvia by Region (2007-2010): Value

Sales in US$ Million for US and Rest of World (includes

corresponding Graph/Chart) 17

Table 3: Global Sales of Janumet by Region (2007-2010): Value

Sales in US$ Million for US and Rest of World (includes

corresponding Graph/Chart) 18

Galvus (Novartis) 18

Onglyza (Bristol-Myers Squibb and AstraZeneca) 19

Table 4: Global Sales of Onglyza (Saxagliptin) Franchise by

Region (2009 & 2010): Value Sales in US$ Million for the US

and Rest of World (includes corresponding Graph/Chart) 19

Tradjenta (Boehringer Ingelheim) 20

A Brief Comparison of Select Marketed Drugs 20

DPP-IV Inhibitor Pipeline 21

5. DIABETES INCIDENCE AND PREVALENCE 22

Table 5: Worldwide Prevalence of Diabetes Mellitus by Region:

2010 & 2030 (includes corresponding Graph/Chart) 22

Diabetes Mellitus Cases Worldwide - A Demographic Analysis by

Geographic Region 23

North America 23

The United States 23

Canada 23

Mexico 23

Table 6: Prevalence of Diabetes Mellitus in North America

(2010 & 2030): Breakdown by Country, Age Group, and Gender

(In '000 People & %) 23

Europe 23

Table 7: Prevalence of Diabetes Mellitus in Europe (2010 &

2030): Breakdown by Country, Age Group, and Gender (In '000

People & %) 24

Asia-Pacific 25

Table 8: Prevalence of Diabetes Mellitus in South East Asia

(2010 & 2030): Breakdown by Country, Age Group, and Gender

(In '000 People & %) 25

Table 9: Prevalence of Diabetes Mellitus in Western Asia

(2010 & 2030): Breakdown by Country, Age Group, and Gender

(In '000 People & %) 26

South & Central America 26

Table 10: Prevalence of Diabetes Mellitus in South & Central

America (2010 & 2030): Breakdown by Country, Age Group, and

Gender (In '000 People & %) 27

Rest of World 28

Table 11: Prevalence of Diabetes Mellitus in Africa (2010 &

2030): Breakdown by Country, Age Group, and Gender (In '000

People & %) 28

Table 12: Prevalence of Diabetes Mellitus in The Middle East

& North Africa (2010 & 2030): Breakdown by Country, Age

Group, and Gender (In '000 People & %) 29

6. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS 30

Physiology of Glucose Homeostasis 30

Glucose Homeostasis in the Fasting Stage 30

Glucose Homeostasis in the Fed Stage 30

What is DPP-4? 30

Introduction to DPP-4 Inhibitors 30

Mechanism of Action of DPP-4 Inhibitors 31

Schematic Representation of DPP-IV Inhibitor' Mechanism of

Action 31

DPP-4 Inhibitors in Combination with Other Anti-diabetic

Medications 31

Advantages of DPP-4 Inhibitors 32

Type-2 Diabetes - The Most Prevalent Form of Diabetes 32

Bio-chemistry of T2DM 32

7. PRODUCT APPROVALS/INTRODUCTIONS 34

Boehringer, Eli Lilly Obtain European Marketing Authorization

for Trajenta 34

Boehringer, Eli Lilly's Tradjenta Receives FDA Approval 34

Bristol-Myers and AstraZeneca Launch Kombiglyze™ XR in the US 34

Bristol-Myers and AstraZeneca Obtain EU Approval for New

Saxagliptin Label Update 35

Ono Pharmaceutical Obtains Additional Indication for Glactiv

in Japan 35

Takeda Obtains Label Extension for Nesina in Japan 35

AstraZeneca and BMS Obtain FDA Approval for Kombiglyze™ XR 36

Novartis Obtains Approval for Vildagliptin in Japan 36

Ono and Banyu Launch Glactiv in Japan 36

Takeda Launches Nesina® in Japan 36

Merck, Sharp & Dohme Introduces Januvia in China 37

Ono and Banyu Receive Japanese Approval for Sitagliptin 37

AstraZeneca and Bristol-Myers Receive EU Marketing

Authorization for Onglyza 37

AstraZeneca and Bristol-Myers Obtain FDA Clearance for Onglyza 37

Merck's Janumet™ Receives EU Approval 38

MSD Pharmaceuticals Introduces Januvia in India 38

Merck Launches Januvia in New Zealand 38

Novartis Obtains EU Approval for Combination Diabetes Drug -

Eucreas 39

Novartis' Diabetes Drug - Galvus Receives EU Approval 39

MSD's JANUVIA® Obtains EU Approval for Treatment of Type 2

Diabetes 39

Merck Obtains FDA Approval for Januvia 40

8. RECENT INDUSTRY ACTIVITY 41

Takeda Resubmits 2 NDAs for Alogliptin in the US 41

Astellas to Divest DPP-4 Inhibitor Patents to Royal Pharma 41

Sun Pharmaceutical Enters into a Partnership Deal with Merck 41

Boehringer Ingelheim and Lilly Enter into Licensing Agreement 41

Kowa Initiates Phase-II Trial of Anagliptin 42

Phenomix Shuts Shop in the Wake of Breakdown of Dutogliptin Deal 42

Forest Labs Opts Out of Anti-Diabetic Drug Deal with Phenomix 42

Double-Crane and LG Life Sciences Enter Agreement for Sale of

LC-15-0444 42

Bristol-Myers Squibb Enters into Collaboration with AstraZeneca 43

Takeda Terminates Development of TAK 100 43

Merck Obtains Positive Opinion from CHMP for Use of

sitagliptin with Insulin 43

Merck and Cigna Ink "Performance-Based Contract" 43

Novartis Terminates Eucreas Development Program in the US 43

Chiesi and Phenomix Ink Development and Commercialization Deal

for Dutogliptin 44

America Stem Cell and Dara Biosciences Sign Material Transfer

Agreement 44

Egis Acquires Marketing License for Januvia in Hungary 44

Novartis Joins Hands with USV to Market Galvus in India 44

Merck and Almirall Enter into an Agreement to Commercialize

Tesavell in Spain 45

Forest Teams Up with Phenomix for Developing DPP-IV Inhibitor

- Dutogliptin 45

Sanwa Kagaku and Kowa Ink Deal to Co-develop DPP-4 inhibitor -

SK-0403 45

Novartis' Diabetes Drug Galvus Faces Delay in FDA Approval 45

9. FOCUS ON SELECT GLOBAL PLAYERS 46

Arisaph Pharmaceuticals, Inc. (US) 46

AstraZeneca Plc. (UK) 46

Boehringer Ingelheim GmbH (Germany) 47

Bristol-Myers Squibb (US) 47

Eli Lilly And Company (US) 48

Merck & Co, Inc. (US) 48

Mitsubishi Tanabe Pharma Corporation (Japan) 49

Novartis AG (Switzerland) 50

Takeda Pharmaceutical Company Limited (Japan) 50

10. GLOBAL MARKET PERSPECTIVE 51

Table 13: World Recent Past, Current and Future Analysis for

DPP-IV Inhibitors by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 51

Table 14: World 10-Year Perspective for DPP-IV Inhibitors by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 52

Table 15: World Recent Past, Current and Future Analysis for

DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin,

Saxagliptin and Others Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 53

Table 16: World 10-Year Perspective for DPP-IV Inhibitors by

Drug Class - Percentage Breakdown of Dollar Sales for

Sitagliptin, Vildagliptin, Saxagliptin and Others Markets for

Years 2008, 2011 and 2017 (includes corresponding Graph/Chart) 54

11. THE UNITED STATES 55

A.Market Analysis 55

Current & Future Analysis 55

Diabetes Pandemic in the US 55

Non-Insulin Products Dominate the Diabetes Therapeutics Market 55

Table 17: US Non-Insulin Anti-Diabetic Market by Drug Class

(2010 & 2017): Percentage Breakdown of Revenues for

Metformin, DPP-4 Inhibitors, Sulfonylureas,

Thiazolidinediones, GLP-1 Analogues, and Others (includes

corresponding Graph/Chart) 56

DPP-IV Inhibitors All Set to Gain Market Share in Oral Anti

-Diabetics 56

Januvia Leads the Way, Will Remain the Top Drug Through 2017 56

Minimal Differentiation Affects Sales of Onglyza 57

Table 18: US Total Prescriptions of Januvia and Onglyza

Analyzed in Terms of Total Prescriptions Since Launch in

Thousands (includes corresponding Graph/Chart) 57

FDA's Issue of Safety Alert on Januvia and Janumet 58

Increasing Scrutiny of NDAs Bodes Tough Time for New Drugs 58

Product Approvals/Launches 59

Strategic Corporate Developments 61

Focus on Select Key Players 63

B.Market Analytics 66

Table 19: The US Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 66

12. CANADA 67

Market Analysis 67

Table 20: Canadian Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 67

13. JAPAN 68

A.Market Analysis 68

Current & Future Analysis 68

Competition in Japanese DPP-IV Inhibitor Market Heats Up 68

Product Approvals/Launches 68

Strategic Corporate Developments 70

Focus on Select Key Players 71

B.Market Analytics 72

Table 21: Japanese Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 72

14. EUROPE 73

A.Market Analysis 73

Current & Future Analysis 73

Treatment Strategies of Type-2 Diabetes in Europe 73

Product Approvals/Launches 73

Strategic Corporate Developments 76

B.Market Analytics 78

Table 22: European Recent Past, Current and Future Analysis

for DPP-IV Inhibitors by Geographic Region - France,

Germany, Italy, UK and Rest of Europe Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 78

Table 23: European 10-Year Perspective for DPP-IV Inhibitors

by Geographic Region - Percentage Breakdown of Dollar Sales

for France, Germany, Italy, UK and Rest of Europe Markets

for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 79

14a. FRANCE 80

Market Analysis 80

Table 24: French Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 80

14b. GERMANY 81

A.Market Analysis 81

Boehringer Ingelheim GmbH - A Key Player 81

B.Market Analytics 82

Table 25: German Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 82

14c. ITALY 83

Market Analysis 83

Table 26: Italian Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 83

14d. THE UNITED KINGDOM 84

A.Market Analysis 84

Current & Future Analysis 84

Blacklisting of Drugs in UK Raises Concerns 84

AstraZeneca Plc. - A Key Player 84

B.Market Analytics 85

Table 27: The UK Recent Past, Current and Future Analysis

for DPP-IV Inhibitors Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 85

14e. REST OF EUROPE 86

A.Market Analysis 86

Novartis AG - A Major Player 86

B.Market Analytics 87

Table 28: Rest of European Recent Past, Current and Future

Analysis for DPP-IV Inhibitors Analyzed with Annual Sales

Figures in US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 87

15. ASIA-PACIFIC 88

A.Market Analysis 88

Current & Future Analysis 88

Overview of Select Markets in the Region 88

India 88

DPP-4 Inhibitor to Garner Increasing Share in Indian

Diabetes Drugs Market 88

Strong Growth Ahead for Anti-Diabetes Products in India 88

First-to-Market Advantage and Unique Strategy Keep Januvia

Ahead of Competition 89

China 89

China Lags in DPP-4 Inhibitors Market, Bodes Robust Growth

Ahead 89

Australia 90

Rising Incidence of Diabetes 90

Diabetes Market - A Window of Opportunity Restricted by PBS 90

Korea 91

Januvia Franchise Reigns in Korean DPP- IV Market 91

Product Approvals/Launches 91

Strategic Corporate Developments 92

B.Market Analytics 93

Table 29: Asia-Pacific Recent Past, Current and Future

Analysis for DPP-IV Inhibitors Analyzed with Annual Sales

Figures in US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 93

16. REST OF WORLD 94

A.Market Analysis 94

Current & Future Analysis 94

A Sneak-Peak at Brazilian Diabetes Market 94

B.Market Analytics 95

Table 30: Rest of World Recent Past, Current and Future

Analysis for DPP-IV Inhibitors Analyzed with Annual Sales

Figures in US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 95

COMPETITIVE LANDSCAPE

Total Companies Profiled: 31 (including Divisions/Subsidiaries - 33)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 10

Japan 10

Europe 7

Germany 1

The United Kingdom 1

Italy 1

Spain 1

Rest of Europe 3

Asia-Pacific (Excluding Japan) 6

------------------------------------------

To order this report:

Biopharmaceutical Industry: Global DPP IV Inhibitors Industry

Biopharmaceutical Business News

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.